Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries is currently trading at Rs. 557.45, up by 18.95 points or 3.52% from its previous closing of Rs. 538.50 on the BSE.

The scrip opened at Rs. 538.50 and has touched a high and low of Rs. 559.60 and Rs. 538.50 respectively. So far 397872 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 854.50 on 05-Aug-2016 and a 52 week low of Rs. 493.00 on 29-May-2017.

Last one week high and low of the scrip stood at Rs. 559.60 and Rs. 534.10 respectively. The current market cap of the company is Rs. 133653.35 crore.

The promoters holding in the company stood at 54.39%, while institutions and non-institutions held 33.49% and 12.13% respectively.

Sun Pharmaceutical Industries and its subsidiaries or associate companies (collectively Sun Pharma) has signed an agreement with The National Institute of Virology (NIV), Pune, an institution of the Indian Council of Medical Research, Department of Health Research, Ministry of Health and Family Welfare , New Delhi, for testing phytopharmaceutical, biologic and chemical entities developed by Sun Pharma against Zika, Chikungunya and Dengue viruses.

Sun Pharma will provide drug molecules to NIV for testing against Zika, Chikungunya and Dengue in model systems. Candidate molecules with encouraging data will then be taken forward for commercial development.

Sun Pharma’s agreement with NIV follows its MOU with Indian Council of Medical Research (ICMR) for conducting joint scientific research and innovation for testing of drugs, biosimilars and vaccines and disease control and elimination programs.